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Abstract 
Background: Infections are a major cause of morbidity and mortality in kidney allograft 
recipients. In this posthoc analysis of a randomized clinical trial which tested the effect of 
denosumab on bone mineral density we assessed the impact of this drug on the incidence and 
severity of infections in the first year after kidney transplantation. 
Methods: In this clinical trial we randomized 90 de novo kidney transplant recipients shortly 
after transplantation to either denosumab on top of standard treatment (calcium and vitamin D) 
(n=46), or to standard treatment alone (n=44). Among all adverse events we analyzed all 
infections that occurred within the first year after transplantation, and compared their 
incidence and severity in both groups. 
Results: Overall we identified more infections (n=146) in the denosumab group than in the 
control group (n=99). The most common infections were urinary tract infection (cystitis) 
(34.9% vs 25.2%), CMV viremia (17.8% vs 24.2%), flu-like syndrome (11.6% vs 14.1%), 
polyoma (BK) viremia (8.2% vs 11.1%), and herpes simplex infections (5.5% vs 4.0%). 
Episodes of urinary tract infection (cystitis) occurred more often in the denosumab than in the 
control group (51 vs 25 episodes in 24 vs 11 patients, p=0.008), whereas episodes of 
transplant pyelonephritis or urosepsis were not more frequent (3 vs 5 episodes).  
Conclusions: This post-hoc analysis reveals that treatment with denosumab to prevent bone 
loss in first-year kidney transplant recipients was associated with more frequent episodes of 
urinary tract infections, whereas other infections occurred with similar frequency in both 
treatment groups. 
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Introduction 
A major cause of morbidity and mortality in kidney transplant recipients are infections 
1
. The 
risk of infection is influenced by a variety of factors including immunosuppressive therapy, 
treatment of rejection episodes, reactivation of a previous latent infection, presence of 
indwelling catheters, nutritional status and uncontrolled glycemia in patients with diabetes 
mellitus 
2-4
. The impact of infections can be reduced by careful pre-transplant screening of 
recipients and donors, vaccinations, post-transplant infection prophylaxis and appropriate 
dosing of the immunosuppressive treatment 
2,5
. 
The incidence and the type of infections that occur after transplantation typically follow a 
characteristic pattern with regard to time after transplantation 
6
. However, the introduction of 
novel therapeutic agents, particularly drugs which affect the immune system or the host 
defense, may lead to unexpected or novel infectious complications. Examples are the 
increasing incidence of BK virus nephropathy 
7,8
 that can be attributed at least in part to the 
introduction of immunosuppressive drugs such as tacrolimus and mycophenolate, or the 
higher risk for Epstein-Barr virus-associated lymphomas in patients treated with the novel 
immunosuppressant belatacept 
9,10
. 
Kidney transplant recipients often have osteopenia or osteoporosis which leads to an 
increased risk for fractures 
11
. Therapeutic options to improve the loss of bone mass include 
supplementation with calcium and vitamin D and its analogues 
12,13
, and treatment with 
bisphosphonates 
14-17
. In a randomized clinical trial we have recently shown that denosumab - 
a fully human monoclonal antibody against Receptor Activator of Nuclear Factor B Ligand 
(RANKL) – effectively increased bone mineral density when given during the first year after 
kidney transplantation 
18
. In that trial we noticed that denosumab unexpectedly increased the 
incidence of urinary tract infections. We therefore sought to analyze in detail all infectious 
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episodes that occurred during this clinical trial, and to obtain more information regarding the 
type and course of the infectious episodes. 
 
Materials and Methods 
Study design 
The trial design has previously been described in detail (NCT01377467) 
18
. In brief, this 
academic study was a 1-year prospective single-center, randomized, parallel-group, open-
label clinical trial in 90 de novo kidney transplant recipients. Patients were randomized to 
receive subcutaneous injections of 60 mg denosumab at baseline and after 6 months (n=46) or 
no treatment (n=44). All patients received calcium (1000 mg) and vitamin D (800 IU or more) 
supplementation as a standard treatment. All patients were followed up in the same institution 
in the first year after transplantation. Study visits were performed at baseline and months 0.5, 
1, 2, 3, 6, and 12. All clinical and routine laboratory values and all adverse events including 
infections were captured with a secured web-based case report form (secuTrial
®
, interActive 
Systems, Berlin, Germany). 
All infectious episodes were carefully reviewed to document their type, severity and duration. 
In particular, all microbiology, virology and serology results were reviewed in all patients to 
classify the infections. 
Urinary tract infection (cystitis) was defined as an episode of local urinary symptoms such as 
dysuria, frequency or urgency in combination with the presence of >10
5
 CFU/mL on urine 
culture with or without leukocyturia. Episodes of urinary tract infection with negative urine 
culture were also counted if clinically suggestive and empirically treated with antibiotics. The 
severity of urinary tract infection was defined according to the Common Terminology Criteria 
for Adverse Events (CTCAE) Version 4.0. 
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Transplant procedure and posttransplant management 
Among all 90 kidney transplants 44 were from deceased donors (48.9%) and 46 from living 
donors (51.1%). Preemptive transplantation was performed in 17 patients (18.9%) and repeat 
transplantation in 14 patients (15.6%). During transplantation a pigtail catheter was inserted 
routinely to stent the transplant ureter, and a Foley catheter to drain the bladder. The Foley 
catheter was removed 4 to 6 days after surgery and the pigtail catheter 6 weeks 
posttransplantation. 
Patients received induction treatment with basiliximab (68.9%) or anti-thymocyte globulin 
(30.0%), together with triple immunosuppression therapy which included a calcineurin 
inhibitor (70% tacrolimus, 30% cyclosporine), mycophenolate and corticosteroids. 
Corticosteroids were tapered and successfully removed from 3 patients (3.3%) after 6 months, 
and from another 42 patients (46.7%) after 12 months. 
All patients received a daily chemoprophylaxis with trimethoprim (80 mg) and 
sulfamethoxazole (400 mg) for Pneumocystis jirovecii and urinary tract infections in the first 
6 months posttransplant. CMV was approached with a preemptive strategy. Thus, CMV 
prophylaxis with daily valganciclovir (900 mg, adapted for renal function) for the first 3 
months was only prescribed to high-risk (D+/R-) and intermediate risk patients (D+/R+; D-
/R+) if they received anti-thymocyte globulin induction treatment. 
 
Statistical analysis 
Categorical data were analyzed with the chi-square test or Fisher’s exact test to check for 
independence of 2 variables. For the analysis of stratified categorical data, the Mantel-
Haenszel test was used. The exact Wilcoxon rank sum test was used to compare for 
differences in ordinal or interval scaled, not normally distributed variables. 
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Results 
The study population included 90 kidney transplant recipients. Patients were randomized after 
a mean (SD) of 15.7 (6.4) days after transplantation to denosumab treatment (n=46) at a dose 
of 60 mg subcutaneously at baseline and at 6 months or no treatment (n=44). Two patients did 
not receive denosumab and another 2 patients received only the baseline injection of 
denosumab. 
The baseline patient characteristics are shown in Table 1. The 2 study groups were generally 
well balanced, except that the denosumab group had more men and more living donor 
transplants. Both study groups were treated with similar immunosuppression. The CMV risk 
profile was similar in both groups. 
During the 12-month study period we recorded a total of 349 adverse events (AE) in the 
denosumab group (7.6 AE per patient) and 273 AE in the control group (6.2 AE per patient), 
of which 146 (41.8%) and 99 (36.3%), respectively, were infections. The number of 
infections per patient tended to be higher in the denosumab than in the control group (median 
3 vs 2 infections, p=0.068), but the number of patients with any infection was not different in 
the 2 treatment groups (41 vs 37; p=0.482). 
Table 2 shows that the most common infections were urinary tract infections (cystitis) 
(31.0%), CMV viremia (20.4%), flu-like syndrome (12.6%), polyoma (BK) viremia (9.3%), 
and herpes simplex infections (4.9%). Of importance, episodes of urinary tract infection 
occurred in more patients in the denosumab than in the control group (51 vs 25 episodes), 
whereas the number of episodes with CMV viremia (26 vs 24), flu-like syndrome (17 vs 14), 
polyoma (BK) viremia (12 vs 11) and herpes simplex infection (8 vs 4) did not differ. 
We noticed 5 acute rejection episodes in 5 patients in the denosumab group and 4 acute 
rejection episodes in 3 patients in the control group. The cumulative amount of corticosteroids 
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over the 12-month study period was similar, amounting to 3.760 ± 1.445 g in the denosumab 
and 3.974 ± 1.727 g in the control group. 
 
Urinary tract infections (cystitis) and pyelonephritis/urosepsis 
Episodes of urinary tract infection (cystitis) occurred in more patients in the denosumab than 
in the control group (24 vs 11 patients, odds ratio (OR) 3.3 [95% CI 1.3-8.0], p=0.008), 
whereas transplant pyelonephritis and urosepsis showed no difference in the 2 groups (3 vs 5 
patients, p=0.480). Clinically, the 51 episodes of urinary tract infection (cystitis) in the 
denosumab group were of mild (3.9%), moderate (76.5%), or severe (19.6%) degree. The 25 
episodes in the control group were of moderate (56.0%) or severe (44.0%) degree. Thus, the 
fraction of severe episodes of urinary tract infections were higher in the control than in the 
denosumab group (p=0.025). Figure 1 displays the cumulative incidence of the urinary tract 
infections in both groups. In the denosumab group there were 4/51 urinary tract infections and 
in the control group 0/25 infection that occurred early in the first 4 to 6 days after 
transplantation while the Foley catheter was in place. In the denosumab group 20/51 urinary 
tract infections and 6/25 infections in the control group occurred in the first 6 weeks after 
transplantation while the ureteral stent was in place. In the denosumab group, 18/51 urinary 
tract infections and 7/25 infections in the control group occurred between 6 and 12 months 
after transplantation, ie at the time when antibiotic prophylaxis had been stopped. Overall, 
two-thirds of the urinary tract infections occurred in the first 6 months after transplantation, 
and did not coincide with the removal of the pigtail catheter 6 weeks posttransplant, or follow 
the application of denosumab at baseline and after 6 months, or follow the removal of the 
antibiotic prophylaxis. In addition there was no difference in the duration of the urinary 
drainage with the Foley catheter or the ureteral stents in both groups. 
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Women tended to be affected by urinary tract infections more often than men (16/33 vs 19/57) 
(p=0.155). As gender was not equally distributed between the treatment groups, the OR of 3.3 
for urinary tract infections under denosumab treatment raised to 4.8 (95% CI 1.7-13.5) when 
controlling for gender. Other parameters did not seem to have an influence on the frequency 
of urinary tract infections. Thus, neither the type of donation (living vs deceased; p=0.361) 
nor the type of induction therapy (ATG vs basiliximab; p=0.424) were associated with the 
occurrence of urinary tract infections. 
The urine cultures were positive in all 25 episodes of urinary tract infection in the control 
group (100%), whereas only 42 of 51 cultures were positive in the denosumab group (82%), 
despite a clear clinical diagnosis of urinary tract infection. The spectrum of urine bacteria was 
similar in the denosumab and control group (Table 3). The most frequent bacteria included 
Escherichia coli (n=23), Klebsiella pneumonia (n=12) and Enterococcus faecalis (n=9). 
Escherichia coli (17/51 vs 6/25 urinary tract infections) and Enterococcus faecalis (8/51 vs 
1/25 urinary tract infections) occurred more frequently in the denosumab than in the control 
group. The pathogen for all 8 episodes of pyelonephritis was Escherichia coli. 
Urinary tract infections were treated with oral (n=55) or intravenous antibiotics (n=21). Oral 
antibiotics were prescribed for 41 (80.4%) infections in the denosumab group and for 14 
infections in the control group (56.0%). In the denosumab group 10 (19.6%) infections were 
treated with intravenous therapy vs 11 (44.0%) infections in the control group. 
 
CMV viremia 
The details regarding CMV viremia are shown in Table 4. CMV viremia occurred with 
similar frequency in both groups (20 vs 18 patients, p=0.805). The median time to CMV 
viremia occurrence after transplantation was similar in both groups. In each group 5 primary 
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infections occurred after stopping the CMV prophylaxis with valganciclovir. The distribution 
of CMV viremia was significantly different for low, intermediate and high risk constellation 
(p=0.003), with most viremias occurring in the intermediate and high risk constellations. 
CMV disease occurred in none of the patients in the denosumab group and in 1 patient in the 
control group. This patient developped diarrhea, and the histologic specimen from the 
colonoscopy confirmed the diagnosis of CMV colitis. Oral valganciclovir was prescribed to 
23 viremias in the denosumab group and 11 viremias in the control group. Intravenous 
ganciclovir was used in 1 case in the denosumab group and 6 cases in the control group. Two 
and 7 cases with intermediate risk constellation received no treatment due to a very low virus 
replication (<2000 copies/ml). In summary, denosumab did not appear to alter the incidence, 
severity and duration of CMV infection. 
 
Flu-like syndromes 
Flu-like syndromes occurred in 12 patients in the denosumab group and 13 patients in the 
control group (p=0.714). A total of 24 of the infections occurred between October and April 
and 7 infections between May and September, corresponding to the seasonal variation. 
 
Polyoma (BK) viremia 
The details regarding BK viremia are shown in Table 4. The number of patients with BK 
viremia was not different between the 2 groups, whereas the median time to BK viremia after 
transplantation occurred significantly earlier in the control group (p=0.049). One case of 
biopsy-proven BK virus nephropathy occurred in the denosumab group and none in the 
control group. In the denosumab group, 5 infections occurred in patients with ATG induction 
and 6 infections with basiliximab induction. In the control group, 4 infections occurred in 
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patients treated with ATG and 7 infections when treated with basiliximab. In summary, 
denosumab did not appear to significantly alter the incidence, severity and duration of BK 
virus infection. 
 
Herpes simplex type 1 and herpes zoster infections 
Herpes simplex type 1 (HSV 1) infections occurred with similar frequency in the denosumab 
and control groups (5 vs 4, p=0.714). One case of a disseminated HSV 1 infection occurred in 
the denosumab group and 1 case of herpes oesophagitis (HSV 1) occurred in the control group. 
Both cases were successfully treated with oral valaciclovir for 10 days. The other cases were 
classical herpes labialis infections. 
One patient in the denosumab group and 2 patients in the control group received oral 
valaciclovir as primary therapy for herpes labialis and 6 patients in the denosumab group and 
none in the control group received local therapy with topical acyclovir. One patient in the 
control group received neither valaciclovir nor acyclovir. 
There were 3 cases of herpes zoster in the denosumab group and none in the control group, 
suggesting that denosumab could promote these infections. None of the cases was a 
disseminated infection. The localization along the dermatomas was in the face, thoracic and 
on the leg. All 3 cases were treated with oral valaciclovir for 10 days and none of the patient 
had a relapse.  
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Other relevant infections 
Wound infections (4 vs 0) as well as cutaneous infections (4 vs 0) were seen more often in the 
denosumab group than in the control group. Thus, although the number of wound and 
cutaneous infections was small, it appears that denosumab may promote these infections. 
 
Discussion 
Denosumab is a new and first-in-class anti-osteoporotic drug which is highly effective in 
preventing vertebral and non-vertebral fractures in postmenopausal women with osteoporosis 
19
 and has shown superior efficacy when compared with bisphosphonates in this patient 
population 
20
. Although generally well tolerated, infections involving the gastrointestinal tract, 
the renal and urinary system and the skin were shown to occur slightly more often in patients 
treated with denosumab compared with placebo 
21-24
. Whether kidney transplant recipients 
under immunosuppressive treatment are at higher risk for infection when treated with 
denosumab has not been studied yet 
6,25
. 
The posthoc analysis of our POSTOP study revealed a higher number of infections in 
denosumab-treated renal transplant recipients compared with patients in the control group. In 
particular, denosumab treatment led to a doubling of the number of urinary tract infections 
(cystitis), whereas other types of infections, particularly opportunistic infections with CMV 
and BK virus were not more common with denosumab treatment. Such a high incidence of 
urinary tract infections was not seen in postmenopausal women treated with denosumab 
19
, 
suggesting that immunosuppressed de novo renal transplant recipients are more vulnerable to 
this type of infection. Specific and nonspecific immune response may be influenced by the 
RANKL system.  
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The mechanisms which lead to such a high number of urinary tract infections are probably 
multifactorial. It has been suggested that the inhibition of the RANK/RANKL pathway with 
denosumab could decrease the resistance to microbial organisms by unknown mechanisms 
26,27
. Renal transplant patients are known to be particularly susceptible to urinary tract 
infections due to structural alterations of the urinary tract which are inherent to the transplant 
procedure, reflux, bladder dysfunction, and the routine insertion of pigtail ureteral and bladder 
catheters. It is known, that vitamin D can have immunomodulatory activities. In our study, the 
serum levels of 25-(OH)-vitamin D and 1, 25-(OH)2-vitamin D progressively increased in 
both groups to similar levels at 12 months, suggesting that the difference in urinary tract 
infections in the 2 groups cannot be explained with the immunomodulatory activities of 
vitamin D
18
. Furthermore, in the setting of strong triple immunosuppression in the first 
months after transplantation denosumab may contribute to a further increase in the incidence 
of these infections. 
Fortunately, the urinary tract infections in both groups represented mostly benign episodes of 
cystitis which could easily be managed with antibiotics, and transplant pyelonephritis or 
urosepsis were not more common in the denosumab group. Furthermore, the severity and 
duration of these infections was not aggravated with denosumab. Somewhat surprising is the 
fact that 18% of the urine cultures were negative in the densoumab group, whereas there were 
no negative cultures in the control group. Thus we cannot exclude that some of these 
clinically diagnosed episodes of urinary tract infection in the denosumab group were in fact 
abacterial, or caused by less traditional microorganisms. Nevertheless, the number of urinary 
tract infections was significantly higher in the denosumab group even after exclusion of the 
cases with negative culture. Thus it is advisable to pay particular attention to the occurrence 
of urinary tract infections when denosumab is used early after renal transplantation, 
AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
14 
 
particularly since these infections are 1 of the major causes of morbidity and rehospitalization 
after kidney transplantation.  
The incidence of pyelonephritis and urosepsis in the first year after kidney transplantation can 
be as high as 9-14% and 3-7%, respectively 
28-31
. As mentioned, the rate of pyelonephritis and 
urosepsis was comparable in both study arms, with 3 episodes (6.5%) in the denosumab group 
and 5 episodes (11.4%) in the control group. The routine use of antibiotic prophylaxis with 
trimethoprim-sulfamethoxazole in the first 6 months post-transplant may have prevented a 
higher incidence of more severe urinary tract infections, as it has been shown in other studies 
32
. Of note, in patients with urinary tract infection the spectrum of urine bacteria was similar 
in the denosumab and the control group. E. coli, Klebsiella pneumoniae and Enterococcus 
faecalis represented the most common infectious agents, as it is seen in the general transplant 
population 
33,34
. Since only 4 patients in the denosumab group and 3 patients in the control 
group had diabetes, we could not make a firm statement regarding the known association 
between diabetes mellitus and urinary tract infections.  
CMV infection is the most common opportunistic infection in kidney transplant patients, 
occurring in approximately 8% of recipients 
35
. Risk factors associated with CMV infection 
include the use of T cell depleting antibodies, the presence of rejection, concurrent infections 
and donor sero-positivity 
36
. In our study, the use of denosumab did not increase the incidence 
of CMV infection in the treatment group. Likewise, denosumab did not appear to increase the 
incidence and severity of BK viremia and BK nephropathy. Because all other infections 
occurred only in very low number of patients, no definitive conclusion regarding the influence 
of denosumab on these infections can be drawn. However, herpes zoster as well as skin and 
wound infections appeared to occur more commonly in denosumab-treated patients. 
In conclusion, posttransplant treatment with denosumab to prevent bone loss is associated 
with more frequent episodes of urinary tract infection, whereas transplant-specific infections 
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occurred with similar frequency in both groups. Caution regarding urinary tract infections and 
possibly wound, skin and herpes zoster infections is advised when using denosumab early 
after renal transplantation when immunosuppression is at the highest level. 
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Figure legend 
 
Figure 1: Cumulative incidence of lower urinary tract infections in the first year after 
transplantation in both study groups 
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Figure 1 
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Table 1. Demographic and clinical characteristics of 90 study patients at baseline 
Characteristic 
Control group 
(N=44) 
Denosumab group (N=46) 
Age — years 49.0 (±12.9) 50.0 (±14.0) 
Male sex — no. (%) 22 (50.0) 35 (76.1) 
White ethnicity — no. (%) 42 (95.5) 44 (95.7) 
Body mass index — kg/m2 25.5 (±5.3) 25.8 (±4.6) 
Pre-transplant dialysis mode — no. (%)   
Hemodialysis 31 (70.5) 26 (56.5) 
Peritoneal dialysis 9 (20.5) 7 (15.2) 
Pre-emptive transplantation 4 (9.1) 13 (28.3.) 
Repeat transplantation — no. (%) 7 (15.9) 7 (15.2) 
Transplant from deceased donor — no. (%) 26 (59.1) 18 (39.1) 
No. of HLA mismatches 3.8 (±1.3) 3.5 (±1.3) 
Panel reactive antibody titer ≥20% — no. 
(%) 
0 (0.0) 0 (0.0) 
Cause of end-stage renal disease — no. (%)   
Chronic glomerulonephritis 11 (25.0) 19 (41.3) 
Diabetic nephropathy 3 (6.8) 4 (8.7) 
Hypertensive/vascular nephropathy 6 (13.6) 2 (4.3) 
Polycystic kidney disease 8 (18.2) 12 (26.1) 
Other hereditary 4 (9.1) 1 (2.2) 
Other 12 (27.3) 8 (17.4) 
Immunosuppression — no. (%)   
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Induction therapy 
†
 44 (100.0) 45 (97.8) 
Tacrolimus 33 (75.0) 30 (65.2) 
Cyclosporine 11 (25.0) 16 (34.8) 
Mycophenolate 44 (100.0) 46 (100.0) 
Corticosteroids 44 (100.0) 46 (100.0) 
CMV status   
High risk (D+/R-) 12 (27.3) 9 (19.6) 
Intermediate risk (D+/R+, D-/R+) 28 (63.6) 24 (52.2) 
Low risk (D-/R-) 4 (9.1) 13 (28.3) 
 
Data are mean ± standard deviation or number (%). 
†
 Patients received basiliximab (68.9%) or 
anti-thymocyte globulin (30.0%). 
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Table 2. Infections in the study groups 
Infections Control group (n=44) Denosumab group (n=46) 
 
No. events 
(%) 
No. patients 
(%) 
No. events 
(%) 
No. patients 
(%) 
Urinary tract infection 
(cystitis) 
25 (25.2) 11 (25.0) 51 (34.9) 24 (52.2) 
Pyelonephritis/Urosepsis 5 (5.1) 5 (11.4) 3 (2.1) 3 (6.5) 
Asymptomatic 
bacteriuria 
0 (0) 0 (0) 1 (0.7) 1 (2.1) 
CMV viremia
†
 24 (24.2) 18 (40.9) 26 (17.8) 20 (43.4) 
Flu-like syndrome 14 (14.1) 13 (29.5) 17 (11.6) 12 (26.1) 
BK viremia
††
 11 (11.1) 11 (25.0) 12 (8.2) 12 (26.1) 
Herpes simplex type 1 4 (4.0) 4 (9.1) 8 (5.5) 5 (10.9) 
Herpes zoster
†††
 0 (0) 0 (0) 3 (2.1) 3 (6.5) 
Oral candidiasis 3 (3.0) 3 (6.8) 6 (4.1) 3 (6.5) 
Mouth ulcer 3 (3.0) 3 (6.8) 3 (2.1) 2 (4.3) 
Gastroenteritis 4 (4.0) 4 (9.0) 1 (0.7) 1 (2.1) 
Wound infection 0 (0) 0 (0) 4 (2.7) 4 (8.7) 
Cutaneous infection 0 (0) 0 (0) 4 (2.7) 4 (8.7) 
Pneumonia 1 (1.0) 1 (2.3) 2 (1.4) 2 (4.3) 
Sinusitis 1 (1.0) 1 (2.3) 2 (1.4) 2 (4.3) 
Sigma diverticulitis 1 (1.0) 1 (2.3) 0 (0) 0 (0) 
Parodontitis 1 (1.0) 1 (2.3) 0 (0) 0 (0) 
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Conjunctivitis 0 (0) 0 (0) 1 (0.7) 1 (2.1) 
Retinitis 1 (1.0) 1 (2.3) 0 (0) 0 (0) 
Otitis media 0 (0) 0 (0) 1 (0.7) 1 (2.1) 
     
Gingivitis 1 (1.0) 1 (2.3) 0 (0) 0 (0) 
Vaginal infection 0 (0) 0 (0) 1 (0.7) 1 (2.1) 
Total 99 (100.0) 37 (84.1) 146 (100) 41 (89.1) 
 
Data are number (%). 
†
 One case of CMV disease in the control group. 
††
 One case of biopsy 
proven BK virus nephropathy in the denosumab group. 
†††
 Classical herpes zoster along 
dermatomas.
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Table 3. Type of urine bacteria in patients with urinary tract infections 
Bacteria Control group Denosumab group Overall 
Escherichia coli 6 (24.0) 17 (33.3) 23 (30.3) 
Klebsiella pneumoniae 6 (24.0) 6 (11.8) 12 (15.8) 
Enterococcus faecalis 1 (4.0) 8 (15.7) 9 (11.8) 
Coagulase-negative 
staphylococcus 
0 (0) 4 (7.9) 4 (5.2) 
Pseudomonas aeruginosa 2 (8.0) 1 (2.0) 3 (3.9) 
Enterococcus faecium 1 (4.0) 0 (0) 1 (1.3) 
Unknown
†
 2 (8.0) 1 (2.0) 3 (3.9) 
Negative culture 0 (0.0) 9 (17.6) 9 (11.8) 
Other 7 (28.0) 5 (9.8) 12 (23.5) 
    
Total 25 (100.0) 51 (100.0) 76 (100.0) 
 
Data are number (%). 
†
 No urine culture available but treated as urinary tract infection. 
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Table 4. Characteristics of CMV and BK virus infections 
Patients with CMV viremia Control group Denosumab group p 
Patients with CMV viremia 18 20 p=0.805 
High risk (D+/R-) 6 5 
p=0.003 
Intermediate risk 
(D+/R+, D-/R+) 
12 14 
Low risk (D-/R-) 0 1 
CMV events    
Total number of events 24 26  
Primary infection 5 5  
CMV disease 1 0  
Time to CMV viremia 
occurrence after 
transplantation (days) 
131.0 (41.5 – 260.0) 106.5 (43.3 – 149.5) p=0.383 
Maximum CMV copies/ml 7920 (2310 - 80477) 6170 (2492 - 35796) p=0.668 
Duration of positivity (days) 54 (35 - 170) 46 (28 - 69) p=0.229 
Treatment time (days) 100 (73 - 195) 109 (66 - 144) p=0.699 
Oral valganciclovir as 
primary therapy 
11 23 
 
Intravenous ganciclovir as 
primary therapy 
6 1 
 
No treatment due to a low 
virus replication (<2000 
copies/ml) in intermediate 
risk constellation 
7 2  
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BKV viremia    
Patients with BK viremia 11 12 p=0.906 
BK viremia (events) 11 12  
Induction with ATG 4 5  
Induction with basiliximab 7 6  
BK virus nephropathy 0 1  
Time to BK viremia 
occurrence after 
transplantation (days) 
82 (53 - 83) 109 (73 - 156) p=0.049 
Maximum BK copies/ml 24172 (7046 - 
299886) 
28332 (1833 - 147218) 
p=0.525 
Duration of positivity (days) 183 (109 - 308) 172 (51 - 411) p=0.833 
 
Data are number, or median (interquartile range). 
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